GWGang Wei

Gang Wei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gang Wei has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Chenfang Zhu

    Department of General Surgery, The Ninth People's Hospital, Medical School of Shanghai Jiaotong University, Shanghai, China

    1 shared publication
  • Jingjing Wu

    Department of Breast, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

    1 shared publication
  • Kexin Chu

    Department of Radiation Oncology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Xiamen, China

    1 shared publication
  • Lina Ma

    Department of Breast, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

    1 shared publication
  • Meilin Qin

    Shanghai Jiao Tong University School of Medicine, 280 Chongqing South Road, Shanghai, 200025, China; Shanghai Medical College of Fudan University, No. 131 Dongan Road, Shanghai, 200032, China

    1 shared publication
  • Mingjuan Liao

    Department of Traditional Chinese Medicine, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

    1 shared publication

Latest Publications

  • Open Access

    Corilagin Alleviates Nonalcoholic Fatty Liver Disease in High-Fat Diet-Induced C57BL/6 Mice by Ameliorating Oxidative Stress and Restoring Autophagic Flux

    by Rong Zhang, Kexin Chu, Nengjiang Zhao, Jingjing Wu, Lina Ma, Chenfang Zhu, Xia Chen, Gang Wei, Mingjuan Liao

    Corilagin (Cori) possesses multiple biological activities. To determine whether Cori can exert protective effects against nonalcoholic fatty liver disease (NAFLD) and its potential mechanisms. C57BL/6 mice were fed with high-fat diet (HFD) alone or in combination with Cori (20 mg/kg, i.p.) and AML12 cells were exposed to 200 μM PA/OA with or without Cori (10 μM or 20 μM). Phenotypes and key indicators relevant to NAFLD were examined both in vivo and in vitro. In this study, Cori significantly ameliorated hepatic steatosis, confirmed by improved serum lipid profiles, and hepatic TC, TG contents, and the gene expression related to lipid metabolism in livers of HFD mice. Moreover, Cori attenuated HFD-mediated autophagy (including mitophagy) blockage by restoring autophagic flux, evidenced by increased number of autophagic double vesicles containing mitochondria, elevated LC3II protein levels, decreased p62 protein levels, as well as enhanced colocalization of autophagy-related protein (LC3, Parkin) and mitochondria. In accordance with this, Cori also reduced the accumulation of ROS and MDA levels, and enhanced the activities of antioxidative enzymes including SOD, GSH-Px, and CAT. In addition, Cori treatment improved mitochondrial dysfunction, evidenced by increased mitochondrial membrane potential (ΔΨm). In parallel with this, Cori decreased mitochondrial DNA oxidative damage, while increased mitochondrial biogenesis related transcription factors expression, mitochondrial DNA content and oxygen consumption rate (OCR). In conclusion, these results demonstrate that Cori is a potential candidate for the treatment of NAFLD via diminishing oxidative stress, restoring autophagic flux, as well as improving mitochondrial functions.